Precision BioSciences (NASDAQ: DTIL)
Precision BioSciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Precision BioSciences Company Info
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
News & Analysis
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys
These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.
About to Buy Penny Stocks? Look at These 2 Companies First
These healthcare stocks offer high risk and high reward, but they aren't nearly as risky as penny stocks.
These Gene-Editing Pioneers Are Making Bold Bets in Agriculture
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine?
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
This Start-up Might Be the Next Gene Editing IPO
An early-stage start-up with an improved version of CRISPR gene editing filed to go public. Investors may want to keep an eye on it.
Why International Flavors & Fragrances, Precision BioSciences, and GameStop Slumped Today
Find out why one of these stocks lost more than half its value.
No CRISPR Required: This Forgotten Gene Editing Stock Is Up 50% in 5 Weeks
Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.